Rockland Trust Co. Sells 2,649 Shares of Johnson & Johnson (NYSE:JNJ)

Rockland Trust Co. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 107,539 shares of the company's stock after selling 2,649 shares during the quarter. Rockland Trust Co.'s holdings in Johnson & Johnson were worth $17,834,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth $29,000. Conquis Financial LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at $33,000. Bernard Wealth Management Corp. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $36,000. Finally, Runnymede Capital Advisors Inc. bought a new stake in Johnson & Johnson during the 4th quarter worth $38,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.2%

JNJ traded up $0.24 during trading on Friday, hitting $156.90. The company's stock had a trading volume of 6,587,488 shares, compared to its average volume of 7,947,693. The firm has a market capitalization of $377.52 billion, a P/E ratio of 23.59, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock's fifty day moving average price is $153.69 and its 200-day moving average price is $153.71. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.31%. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on JNJ. Royal Bank of Canada reissued an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 5th. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.